Followers | 130 |
Posts | 14996 |
Boards Moderated | 1 |
Alias Born | 06/04/2018 |
Tuesday, June 18, 2019 2:20:47 PM
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that it will present edasalonexent, a novel NF-kB inhibitor in Phase 3 development for the treatment of Duchenne muscular dystrophy (DMD), at two upcoming meetings: the Symposium on M...
Read the whole news https://marketwirenews.com/news-releases/catabasis-pharmaceuticals-to-present-at-upcoming-symposium-on-muscle-bone-interaction-in-duchenne-muscular-dystrophy-and-parent-project-muscular-dystrophy-25th-annual-conference-8373896.html
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM